Everfront Biotech Holding Co Ltd filed a Form F-1 registration statement for an initial public offering on 2025-01-03. It has amended it 2 times. As of its latest filing, on 2025-12-11, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have reserved the symbol “ EFB ” for the purpose of listing our Ordinary Shares on the Nasdaq Capital Market (“Nasdaq”).From the F-1/A filed 2025-12-11
Use of proceeds
We plan to use the net proceeds we receive from this offering for the following purposes.From the F-1/A filed 2025-12-11
Revenue
Therefore, we generated no revenue from product sales in the year ended December 31, 2023, and the revenue of $79,908 recorded in the year ended December 31, 2022 was the service revenue from the fibroblast culture process research commissioned by the related party Xi Yue Biomedicine Inc. (formerly Guang-Li Biomedicine Inc.).From the F-1 filed 2025-01-03
Net loss or income
The Company has suffered net losses of $581,938 and $787,712 for the six months ended June 30, 2025 and 2024, respectively, and used net cash in operating activities of $681,394 and $785,070 for the six months ended June 30, 2025 and 2024, respectively, and has an accumulated deficit of $22,378,190 as of June 30, 2025.From the F-1/A filed 2025-12-11
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-03 | Registration statement filed (foreign issuer) | F-1 |
| 2025-06-23 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-12-11 | Registration statement amended (foreign issuer) | F-1/A |
Tools for this story
Each opens in a new tab, filled in for Everfront Biotech Holding Co Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.